ESPE Yearbook of Paediatric Endocrinology

Brief Summary: This phase 2, double-blind, placebo-controlled trial, randomized 91 people (10-30 years-old) diagnosed with type 1 diabetes (T1D) within the previous 100 days to receive either oral baricitinib (n=60) or placebo (n=31) for 48 weeks. Baricitinib was safe and preserved the capacity of β-cells to secrete insulin.Baricitinib is a Janus kinase (JAK) inhibitor blocking cytokine signalling and is already an effective disease-modifying treatm...